Sight Sciences Boosts 2026 Revenue Guidance on Strong Q1 Growth
Event summary
- Sight Sciences reported Q1 2026 revenue of $19.7M, up 13% YoY.
- Interventional Dry Eye revenue surged 244% YoY to $1.4M.
- Company won $55.4M in damages and a 10% royalty on Hydrus® revenue in Alcon litigation.
- Raised full-year 2026 revenue guidance to $83M–$89M (7–15% growth).
- Cash usage improved 40% YoY to $7M in Q1 2026.
The big picture
Sight Sciences' strong Q1 performance reflects its dual focus on glaucoma and dry eye markets, where it competes with larger players like Alcon. The litigation win provides a financial tailwind, but the company's ability to convert that into sustained growth will depend on execution in high-margin segments. The healthcare technology sector is increasingly consolidating, making strategic differentiation critical.
What we're watching
- Revenue Growth
- Whether Sight Sciences can sustain its Interventional Dry Eye momentum and expand standalone glaucoma interventions.
- Litigation Impact
- How the ongoing royalty from Alcon litigation will affect long-term financials and competitive positioning.
- Operational Efficiency
- The pace at which the company can maintain cost discipline while scaling commercial efforts.
Related topics